误用儿童约束系统对头颈部损伤的评估(以PIPER儿童模型模拟交通事故)(摘译)

近年来,道路上行驶的车辆不断增加。截至2016年,欧盟注册的车辆已达2.57亿辆。据不完全统计,全球每年因道路交通伤害造成的死亡人数约为135万。仅在2004年就有约262000名儿童(19岁以下)在交通事故中丧生。道路交通伤害已成为威胁人类的十大死因之一,因此汽车的安全系统至关重要。     

Tandem pore TWIK-related potassium channels and neuroprotection

TWIK-related potassium channels(TREK) belong to a subfamily of the two-pore domain potassium channels family with three members, TREK1, TREK2 and TWIK-related arachidonic acid-activated potassium channels. The two-pore domain potassium channels is the last big family of channels being discovered, therefore it is not surprising that most of the information we know about TREK channels predominantly comes from the study of heterologously expressed channels. Notwithstanding, in this review we pay special attention to the limited amount of information available on native TREK-like channels and real neurons in relation to neuroprotection. Mainly we focus on the role of free fatty acids, lysophospholipids and other neuroprotective agents like riluzole in the modulation of TREK channels, emphasizing on how important this modulation may be for the development of new therapies against neuropathic pain, depression, schizophrenia, epilepsy, ischemia and cardiac complications.     

CT影像评估不透射线药物洗脱微球经动脉化学栓塞术后药物剂量在兔肿瘤模型中的分布

正摘要目的探讨在兔肿瘤模型中用不透射线的药物洗脱微球(DEB)行经动脉化学栓塞术(TACE)后,CT影像中微球的位置和衰减情况与进入肝脏的药物含量和分布之间的     

低对比度低密度局灶性小病灶的CT检测能力:迭代重建与滤过反投影重建

正摘要目的研究在11种不同的辐射剂量下两大CT设备公司滤过反投影(FBP)和迭代重建(IR)算法分别对低对比度低密度小病灶(≤1cm)的检测能力。材料与方法低对比     

在钆塞酸增强MRI中通过肝细胞摄取率来定量评价肝功能

正目的探讨源于钆塞酸增强MRI的肝细胞摄取率是否与肝功能的定量测量有关,并帮助识别大范围肝切除术的禁忌证。材料与方法在2016年8月—2016年10月期     

RECIST版本1.1对转移瘤反应评估的有效性:一项前瞻性多阅片人研究

正目的采用实体瘤疗效评价标准(RECIST)v1.1确定靶病变选择与转移性癌行全身细胞毒性和/或靶向治疗病人的治疗反应分类之间的相关性。材料与方法该前瞻性多     

心血管MRI评估主动脉瓣狭窄病人的主动脉弹性:比较二叶型和三叶型主动脉瓣

正摘要目的比较二叶型主动脉瓣(BAV)和三叶型主动脉瓣(TAV)的主动脉瓣狭窄(AS)病人在MRI上的主动脉大小和弹性参数。方法 174例无症状中-重度AS病人[平均     

From regenerative strategies to pharmacological approaches:can we fine-tune treatment for Parkinson's disease?

Parkinson's disease is the second most prevalent neurodegenerative disorder worldwide.Clinically,it is characterized by severe motor complications caused by progressive degeneration of dopaminergic neurons.Current treatment is focused on mitigating the symptoms through the administration of levodopa,rather than on preventing dopaminergic neuronal damage.Therefore,the use and development of neuroprotective/disease-modifying strategies is an absolute need that can lead to promising gains on translational research of Parkinson's disease.For instance,N-acetylcysteine,a natural compound with strong antioxidant effects,has been shown to modulate oxidative stress,preventing dopamine-induced cell death.Despite the evidence of neuroprotective and modulatory effects of this drug,as far as we know,it does not induce per se any regenerative process.Therefore,it would be of interest to combine the latter with innovative therapies that induce dopaminergic neurons repair or even differentiation,as stem cell-based strategies.Stem cells secretome has been proposed as a promising therapeutic approach for Parkinson's disease,given its ability to modulate cell viability/preservation of dopaminergic neurons.Such approach represents a shift in the paradigm,showing that cell-transplantation free therapies based on the use of stem cells secretome may represent a potential alternative for regenerative medicine of Parkinson's disease.Thus,in this review,we address the current understanding of the potential combination of stem cell free-based strategies and neuroprotective/disease-modifying strategies as a new paradigm for the treatment of central nervous system neurodegenerative diseases,like Parkinson's disease.     

Prosthetic urology:past,present,and future

The global population is collectively getting older,and age is directly correlated with erectile dysfunction(ED).With the advent of effective oral agents and wide availability of the Internet,a larger portion of the population is becoming aware of the different treatment options for men with ED.     

妊娠期间高血压的严格与非严格控制

<正>高血压严格与非严格控制对妊娠并发症影响不明确。方法:用开放的国际多中心试验,选择妊娠14周整至33周6d的孕妇,此前无蛋白尿或妊娠高血压,诊室舒张压90~105(若孕妇正服降压药,则为85~105mm Hg,1mm Hg=0.133kPa,胎儿存活)。入选孕妇随机分为非严格控制组(舒张压靶目标100mm Hg)或严格控制组(舒张压靶目标85mm Hg)。初级终点是终止妊娠或出生后28d内加强新生儿监